دورية أكاديمية
Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
| العنوان: | Erenumab in highly therapy-refractory migraine patients: First German real-world evidence |
|---|---|
| المؤلفون: | Armin Scheffler, Olga Messel, Sebastian Wurthmann, Michael Nsaka, Christoph Kleinschnitz, Martin Glas, Steffen Naegel, Dagny Holle |
| المصدر: | The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-5 (2020) |
| بيانات النشر: | BMC, 2020. |
| سنة النشر: | 2020 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | 1. migraine, 2. erenumab, 3. therapy, 4. real-world, 5. CGRP antibody, Medicine |
| الوصف: | Abstract Background Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the first specific migraine prophylactic medication. Erenumab is the only CGRP mAB targeting the CGRP receptor. Clinical data regarding efficacy and tolerability of erenumab in highly therapy-refractory patients are not available, yet, although many patients treated with CGRP mAB under real world conditions can be considered as highly therapy-refractory. Methods Clinical routine data of highly therapy-refractory migraine patients treated with erenumab 70 mg for 3 months between November 2018 and December 2019 in the West German Headache Center, University Hospital Essen, Germany, were analysed. Monthly migraine days (MMD), monthly headache days (MHD) and days of acute medication intake (AMD) were assessed. Statistical analysis was performed using the Wilcoxon test. Descriptive statistics were performed to evaluate changes of vegetative symptoms, acute medication response, side effects, as well as treatment satisfaction. Results Complete clinical data were available for 26 episodic (EM) and 74 chronic (CM) migraineurs. Sixty-six % (n = 49) of CM patients had an additional medication overuse headache (MOH). After 3 months 57.7% of EM patients and 41.9% of CM patients had a 50% or greater reduction of MMD. The mean number of MMD was reduced by 3.43 (SE 1.26) in EM, and by 4.72 (SE 0.87) in CM. Thirty-nine patients (52.7%) returned from chronic to episodic course of migraine. After 3 months, 23 patients (46.9%) were not suffering from a MOH anymore. Conclusions Erenumab seems to be a promising therapeutic option in highly therapy-refractory migraine patients. Trial registration Retrospective registered. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1129-2369 1129-2377 |
| العلاقة: | http://link.springer.com/article/10.1186/s10194-020-01151-0Test; https://doaj.org/toc/1129-2369Test; https://doaj.org/toc/1129-2377Test |
| DOI: | 10.1186/s10194-020-01151-0 |
| الوصول الحر: | https://doaj.org/article/9b13ce192c42460084d6db6126af5e7bTest |
| رقم الانضمام: | edsdoj.9b13ce192c42460084d6db6126af5e7b |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 11292369 11292377 |
|---|---|
| DOI: | 10.1186/s10194-020-01151-0 |